Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Although wheat and gluten containing food products are generally considered to be healthy, a large number of individuals in the general population reduces or limits their intake and/or replaces wheat by other grains because of possible symptoms. This non-coeliac wheat sensitivity (NCWS) is accompanied by a range of (extra-)intestinal complaints soon after consuming wheat, which improve after wheat withdrawal. Evidence for a biological mechanism and for the exact contributing compound is limited. Furthermore, the impact of grain type, bread processing and the resulting compositional changes in bread on gastrointestinal tolerability in NCWS is unclear, especially as consumed part of a typical daily human diet.
The objective of this study is to investigate the effects of well-characterised breads on (extra-)intestinal symptoms in individuals with NWGS using two double-blind randomized cross-over design (study A and B). Subjects are required to avoid any products that cause GI symptoms (e.g. wheat products) during the trial. The investigators hypothesize that grain type and processing will have a different effect on the primary outcomes.
In addition, we want to explore the in vitro effect of each bread type on gut microbiota composition and activity.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Medical history of coeliac disease, wheat allergy, inflammatory bowel disease, presence of an organic gastrointestinal (GI) disease (such as inflammatory bowel disease) or other disease which may interfere with NCWS symptoms (upon judgment of the physician-clinical investigator (Dr. Keszthelyi, Gastroenterologist MUMC+));
Previous major abdominal surgery or radiotherapy interfering with gastrointestinal function:
Use of medication potentially influencing gastrointestinal function and/or NCWS symptoms is allowed, provided that dosing has been stable for ≥ 1 month before enrolment;
Administration of probiotic, prebiotic supplements, investigational drugs or participation in any scientific intervention study, which may interfere with this study (to be decided by the principle investigator), in the 14 days prior to the study;
Excessive use of alcohol (>15 alcoholic units per week), or other drugs;
Plan to lose weight or follow a specific weight loss diet within the study period;
Current malignancy;
Pregnancy or breastfeeding;
Participation in any scientific intervention study, which may interfere with this study;
Insufficient fluency of the Dutch language.
Follow-up measurement - inclusion criteria
Follow-up measurement - exclusion criteria in addition to the criteria listed above:
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal